title: Inward current oscillation underlying tonic contraction caused via ETA receptors in pig detrusor smooth muscle.
abstract: Endothelin-1 (ET-1) is a powerful vasoconstricting peptide. Recent studies showed synthesis of ET-1 and the presence of ET receptors in urinary bladder smooth muscle cells. In the present study, we investigated the possible role of ET-1 in detrusor contraction and its underlying mechanisms in terms of electrical activity. ET-1 caused dose-dependent tonic contraction of bladder smooth muscle strips. Whole cell patch-clamp experiments revealed that ET-1 induced a single transient inward current in the majority of detrusor cells and that additional inward current oscillations were induced in one-third of the cells. The inward current oscillation and tonic contraction shared several characteristic features: 1) both activities lasted for a considerable time after ET-1 washout and 2) only prior application of ETA receptor antagonists, not ETB receptor antagonists, significantly suppressed ET-1-induced contractions and the oscillating inward currents. It was concluded that the inward current oscillation underlies ET-1-induced tonic contraction. Experiments with ion substitution and channel blockers suggested that periodic activation of Ca2+-activated Cl- channels caused the oscillating inward currents.
authors.affiliation: Department of Cell Physiology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
authors.forename: Shunichi
authors.initials: S
authors.lastname: Kajioka
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Nakayama
authors.forename: Rachel
authors.initials: R
authors.lastname: McCoy
authors.forename: Gordon
authors.initials: G
authors.lastname: McMurray
authors.forename: Kihachiro
authors.initials: K
authors.lastname: Abe
authors.forename: Alison F
authors.initials: AF
authors.lastname: Brading
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D018118:Chloride Channels / Q000502:physiology; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology*; D009130:Muscle, Smooth / Q000502:physiology*; D009543:Nifedipine / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D010456:Peptides, Cyclic / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D044022:Receptor, Endothelin A / Q000502:physiology*; D013552:Swine; D001743:Urinary Bladder / Q000502:physiology*
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D018118:Chloride Channels; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D044022:Receptor, Endothelin A; C086539:BQ 788; D009543:Nifedipine; C072247:cyclo(Trp-Asp-Pro-Val-Leu); D002118:Calcium